KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Mannkind (MNKD) EPS (Weighted Average and Diluted) (2015 - 2026)

Mannkind (MNKD) reported EPS (Weighted Average and Diluted) of -$0.05 for Q1 2026, down 225.0% year-over-year from $0.04 in Q1 2025, and little changed on a QoQ basis from -$0.05 in Q4 2025.

Mannkind (MNKD) has 11 years of EPS (Weighted Average and Diluted) data on file, last reported at -$0.05 in Q1 2026.

  • Quarterly EPS (Weighted Average and Diluted) fell 225.0% year-over-year to -$0.05 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$0.07 (down 170.0% YoY) and the FY2025 annual result came in at $0.02, down 80.0% from the prior year.
  • EPS (Weighted Average and Diluted) held at -$0.05 in Q1 2026 per MNKD's latest filing, from -$0.05 in the prior quarter.
  • Across five years, EPS (Weighted Average and Diluted) topped out at $0.04 in Q1 2024 and bottomed at -$0.11 in Q2 2022.
  • The 5-year median for EPS (Weighted Average and Diluted) is -$0.01 (2024), against an average of -$0.02.
  • The widest annual swing landed in 2024, when EPS (Weighted Average and Diluted) jumped 300.0%; it then sank 266.67% in 2025.
  • Tracing MNKD's EPS (Weighted Average and Diluted) over 5 years: stood at -$0.07 in 2022, then jumped by 114.29% to $0.01 in 2023, then jumped by 200.0% to $0.03 in 2024, then slumped by 266.67% to -$0.05 in 2025, then changed by 0.0% to -$0.05 in 2026.
  • Per Business Quant, the three latest MNKD EPS (Weighted Average and Diluted) figures stand at -$0.05 (Q1 2026), -$0.05 (Q4 2025), and $0.03 (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EPS (Weighted Avg. Diluted) (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -4.43
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn 3,086.42
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 0.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 4.02
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 6.75
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 1.51
10 Mannkind 1.09 Bn 956.66 Mn 82.66 Mn -0.05

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 -0.05
Dec 31, 2025 -0.05
Sep 30, 2025 0.03
Jun 30, 2025 0.00
Mar 31, 2025 0.04
Dec 31, 2024 0.03
Sep 30, 2024 0.04
Jun 30, 2024 -0.01
Mar 31, 2024 0.04
Dec 31, 2023 0.01
Sep 30, 2023 0.01
Jun 30, 2023 -0.02
Mar 31, 2023 -0.04
Dec 31, 2022 -0.07
Sep 30, 2022 -0.06
Jun 30, 2022 -0.11
Mar 31, 2022 -0.10
Dec 31, 2021 -0.11
Sep 30, 2021 -0.02
Jun 30, 2021 -0.14
Dec 31, 2020 -0.12
Dec 31, 2018 -0.06
Sep 30, 2018 -0.16
Jun 30, 2018 -0.16
Mar 31, 2018 -0.25
Dec 31, 2017 -0.28
Sep 30, 2017 -0.31
Jun 30, 2017 -0.35
Mar 31, 2017 -0.17
Dec 31, 2016 0.56
Sep 30, 2016 1.31
Jun 30, 2016 -0.33
Mar 31, 2016 -0.29
Dec 31, 2015 -4.31
Sep 30, 2015 -0.08